Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Myeloid 2Classical hematology 1

Conditions

Hematologic Neoplasms 4Myelodysplastic Syndromes 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Leukemia, Prolymphocytic, T-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Primary Myelofibrosis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Plasma Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hematologic Diseases 1Graft vs Host Disease 1Carcinoma, Non-Small-Cell Lung 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 131fludarabine phosphate 108Mycophenolic Acid 92Peripheral Blood Stem Cell Transplantation 91Whole-Body Irradiation 80Tacrolimus 78Busulfan 64Cyclosporine 60fludarabine 55Melphalan 55Filgrastim 54Antilymphocyte Serum 48Methotrexate 41Radiotherapy 39Etoposide 35Rituximab 33Granulocyte Colony-Stimulating Factor 27Sirolimus 25Cytarabine 23Stem Cell Transplantation 21Cord Blood Stem Cell Transplantation 21thymoglobulin 20Thiotepa 19Methylprednisolone 18sargramostim 17Cyclosporins 16Carmustine 16Alemtuzumab 16Therapeutics 13Psychiatric Rehabilitation 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hodgkin Disease × itacitinib × Other hematologic neoplasm × Clear all
NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Incyte Corporation

Phase 1 Terminated
84 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT03755414 2025-04-06

Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Washington University School of Medicine

Phase 1 Completed
55 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡